Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The aim is to create new genomics solutions that could combat cancer and advance market access
Forex gains stood at Rs 20 crore for the quarter
The company has been consistently reducing debt
Total income grew in the quarter
Dr. Reddy's has the rights to distribute 250mn doses in India
Subscribe To Our Newsletter & Stay Updated
